Prevalence and Risk Factors of Nephrotoxicity Among Adult Cancer Patients at Mbarara Regional Referral Hospital

References

• GLOBOCAN. New global cancer data; 2020. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data. Accessed May 30, 2021.
   Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289.27253694
   PubMed Web of Science ®Google Scholar
• Horie S, Oya M, Nangaku M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol. 2018;22(1):210–244. doi:10.1007/s10157-017-1448-z28856465
   PubMed Web of Science ®Google Scholar
• Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e207. doi:10.1016/S1470-2045(19)30145-730942181
   PubMed Web of Science ®Google Scholar
• Mieczkowski M, Matuszkiewicz-Rowińska J, Kościelska M. [Anti-cancer agents nephrotoxicity]. Wiadomosci Lekarskie. 2015;68(4 Pt 2):650–654. Polish.27162304
   PubMedGoogle Scholar
• Vaseghi G, Abed A, Jafari E, Eslami N, Eshraghi A. Assessment of adverse drug reaction due to cancer chemotherapy in a teaching oncology hospital in Isfahan, Central of Iran. Rev Recent Clin Trials. 2016;11(3):266–272. doi:10.2174/157488711066615081811264826282897
   PubMedGoogle Scholar
• Marvin JL, Levine BJ, Papas M, Rosini JM. An evaluation of the incidence of nephrotoxicity after a loading dose of vancomycin in patients with severe renal impairment. J Emerg Med. 2019;56(6):701–708. doi:10.1016/j.jemermed.2019.03.02031029400
   PubMed Web of Science ®Google Scholar
• Małyszko J, Kozłowska K, Kozłowski L, Małyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dialys Transplant. 2016;32(6):924–936.
   Web of Science ®Google Scholar
• Rébé C, Demontoux L, Pilot T, Ghiringhelli F. Platinum derivatives effects on anticancer immune response. Biomolecules. 2019;10(1):13. doi:10.3390/biom10010013
   PubMed Web of Science ®Google Scholar
• Faig J, Haughton M, Taylor RC, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2018;41(5):432–440. doi:10.1097/COC.000000000000030127281266
   PubMed Web of Science ®Google Scholar
• Gbaguidi GN, Houehanou CY, Amidou SA, Vigan J, Houinato DS, Lacroix P. Prevalence of abnormal kidney function in a rural population of Benin and associated risk factors. BMC Nephrol. 2021;22(1):116. doi:10.1186/s12882-021-02316-y33789608
   PubMed Web of Science ®Google Scholar
• Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. APJCP. 2015;16(3):1117–1122. doi:10.7314/APJCP.2015.16.3.111725735341
   PubMedGoogle Scholar
• Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609–619. doi:10.1634/theoncologist.2016-031928438887
   PubMed Web of Science ®Google Scholar
• Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs–an underestimated problem? Acta Clin Belg. 2011;66(5):337–345.22145268
   PubMed Web of Science ®Google Scholar
• Silver SA, Chertow GM. The economic consequences of acute kidney injury. Nephron. 2017;137(4):297–301. doi:10.1159/000475607
   PubMed Web of Science ®Google Scholar
• Ndagije H, Nambasa V, Namagala E, et al. Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda. Drug Safety. 2015;38(4):395–408. doi:10.1007/s40264-015-0277-925749663
   PubMed Web of Science ®Google Scholar
• Wu H, Huang J. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19(7):559–567. doi:10.2174/138920021866617110815441929119923
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE); 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50. Accessed May 30, 2021.
   Google Scholar
• Shahbaz H, Gupta M. Creatinine clearance. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
   Google Scholar
• Variyath AM, Brobbey A, Chen F. Variable selection in multivariate multiple regression. PLoS One. 2020;15(7):e0236067. doi:10.1371/journal.pone.023606732678828
   PubMed Web of Science ®Google Scholar
• Mohri J, Katada C, Ueda M, et al. Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. J Transl Intern Med. 2018;6(1):32–37. doi:10.2478/jtim-2018-0007
   PubMed Web of Science ®Google Scholar
• Mwenda V, Githuku J, Gathecha G, Wambugu BM, Roka ZG, Ong’or WO. Prevalence and factors associated with chronic kidney disease among medical inpatients at the Kenyatta National Hospital, Kenya, 2018: a cross-sectional study. Pan Afr Med J. 2019;33:321. doi:10.11604/pamj.2019.33.321.1811431692795
   PubMed Web of Science ®Google Scholar
• Kalima N, Gabriel B, Muhindo R, Muyingo A. Chronic kidney disease in patients admitted to the medical ward of Mbarara Regional Referral Hospital in southwestern Uganda: prevalence and associated factors. Int J Med Biomed Res. 2015;4:107–116.
   Google Scholar
• Hoek J, Bloemendal KM, van der Velden LA, et al. Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers. 2016;8(2):21. doi:10.3390/cancers8020021
   PubMed Web of Science ®Google Scholar
• Tanaka M, Horinouchi H. Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. ESMO Open. 2018;3(4):e000342.29765771
   PubMed Web of Science ®Google Scholar
• Zhang QY, Wang FX, Jia KK, Kong LD. Natural product interventions for chemotherapy and radiotherapy-induced side effects. Front Pharmacol. 2018;9:1253. doi:10.3389/fphar.2018.0125330459615
   PubMed Web of Science ®Google Scholar
• Wen J, Zeng M, Shu Y, et al. Aging increases the susceptibility of cisplatin-induced nephrotoxicity. Age (Dordrecht, Netherlands). 2015;37(6):112. doi:10.1007/s11357-015-9844-3
   PubMed Web of Science ®Google Scholar
• Duan Z, Cai G, Li J, Chen X. Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol. 2020;12:1758835920923430. doi:10.1177/175883592092343032489432
   PubMed Web of Science ®Google Scholar
• Wang X, Bonventre JV, Parrish AR. The aging kidney: increased susceptibility to nephrotoxicity. Int J Mol Sci. 2014;15(9):15358–15376. doi:10.3390/ijms15091535825257519
   PubMed Web of Science ®Google Scholar
• Fusco S, Garasto S, Corsonello A, et al. Medication-induced nephrotoxicity in older patients. Curr Drug Metab. 2016;17(6):608–625. doi:10.2174/138920021766616040611595927048182
   PubMed Web of Science ®Google Scholar
• Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L. Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol. 2020;21(1):19. doi:10.1186/s40360-020-0398-332122396
   PubMed Web of Science ®Google Scholar
• Hsu CN, Lee CT, Su CH, et al. Incidence, outcomes, and risk factors of community-acquired and hospital-acquired acute kidney injury: a retrospective cohort study. Medicine. 2016;95(19):e3674. doi:10.1097/MD.000000000000367427175701
   PubMed Web of Science ®Google Scholar
• Santos MLC, de Brito BB, da Silva FAF, Botelho A, de Melo FF. Nephrotoxicity in cancer treatment: an overview. World J Clin Oncol. 2020;11(4):190–204. doi:10.5306/wjco.v11.i4.19032355641
   PubMed Web of Science ®Google Scholar
• Souza VB, Silva EN, Ribeiro ML, Martins Wde A. Hypertension in patients with cancer. Arq Bras Cardiol. 2015;104(3):246–252.25742420
   PubMed Web of Science ®Google Scholar
• Wertman JN, Melong N. The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model. Elife. 2020;9:e56235.32720645
   PubMed Web of Science ®Google Scholar
• Vasconcellos VF, Marta GN, Da silva EM, Gois AF, de Castria TB, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2020;1(1):Cd009256.31930743
   PubMed Web of Science ®Google Scholar
• Workalemahu G, Abdela OA. Chemotherapy-related adverse drug reaction and associated factors among hospitalized paediatric cancer patients at hospitals in North-West Ethiopia. Drug Healthc Patient Saf. 2020;12:195–205.33177883
   PubMed Web of Science ®Google Scholar
• Barnett LMA, Cummings BS. Nephrotoxicity and renal pathophysiology: a contemporary perspective. Toxicol Sci. 2018;164(2):379–390. doi:10.1093/toxsci/kfy15929939355
   PubMed Web of Science ®Google Scholar
• McSweeney KR, Gadanec LK. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers. 2021;13(7):1572.33805488
   PubMed Web of Science ®Google Scholar